INTRODUCTIONThe effects of pimobendan on the heart rhythm in cats are unknown. The purpose of this pilot study was to evaluate the effect of pimobendan on the cardiac rhythm and selected echocardiographic parameters of cats.ANIMALS, MATERIALS, AND METHODSSix clinically healthy cats received each of four medication protocols for 15 days, with a washout period of at least one month between each protocol. The protocols were, pimobendan 0.5 mg/kg twice daily (high dosage group), pimobendan 0.25 mg/kg twice daily (standard dosage group), pimobendan 0.125 mg/kg twice daily (low dosage group), and Biofermin R, one tablet twice daily (placebo group). Twenty-four-hour ambulatory electrocardiogram recordings, blood pressure measurements, and echocardiographic examinations were performed after two weeks of each medication protocol. Electrocardiographic, echocardiographic, and blood pressure parameters were compared between the four groups.RESULTSThe total number of escape/idioventricular/idiojunctional complexes in the high dosage group was significantly higher compared with the placebo, low dosage, and standard dosage groups (p < 0.001). The blood pressure; total number of heart beats per day; and mean, minimum, and maximum heart rates were not significantly different between the groups. The longitudinal strain rate and calculated cardiac output were significantly increased in the high and standard dosage groups.CONCLUSIONSThe administration of pimobendan, especially at high doses, was associated with increased numbers of escape/idioventricular/idiojunctional complexes in some cats and echocardiographic parameters. Further studies are warranted to investigate both the mechanism underlying the observed changes and what, if any, clinical implications these changes might have in cats with heart disease.

2020-06-01·Helicobacter2区 · 医学

Effect of probiotics during vonoprazan‐containing triple therapy on gut microbiota in Helicobacter pylori infection: A randomized controlled trial

2区 · 医学

Article

作者: Kakiuchi, Toshihiko ; Okuda, Masumi ; Yamaguchi, Daisuke ; Hashiguchi, Kazutoshi ; Yamamoto, Kentaroh ; Matsuo, Muneaki ; Imamura, Ichiro ; Fujioka, Yasuhiko ; Nakayama, Aiko ; Mizoe, Akihiko ; Kawakubo, Hiroharu

AbstractBackgroundProbiotics are beneficial to patients with Helicobacter pylori infections by modulating the gut microbiota. Biofermin‐R (BFR) is a multiple antibiotic‐resistant lactic acid bacteria preparation of Enterococcus faecium 129 BIO 3B‐R and is effective in normalizing the gut microbiota when used in combination with antibiotics. This study aimed to determine the effect of BFR in combination with vonoprazan (VPZ)‐based therapy on gut microbiota.MethodsPatients with positive urinary anti‐H pylori antibody test (primary test) and fecal H pylori antigen test (secondary test) were examined. Patients in group 1 (BFR−) received VPZ (20 mg twice daily), amoxicillin (750 mg twice daily), and clarithromycin (400 mg twice daily) for 7 days. Patients in group 2 (BFR+) received BFR (3 tablets/day) for 7 days, in addition to the aforementioned treatments. Following treatment, the relative abundance, α‐diversity, and β‐diversity of gut microbiota were assessed.ResultsSupplementation with BFR prevented the decrease in a‐diversity after eradication therapy (Day 7). β‐diversity was similar between groups. The incidence rate of diarrhea was non‐significantly higher in the BFR− than in the BFR+ group (73.1% vs 56.5%; P = .361). Stool consistency was comparable in the BFR+ group on Days 7 and 1 (3.86 ± 0.95 vs 3.86 ± 1.46; P = .415).ConclusionBiofermin‐R combined with VPZ‐based therapy resulted in higher microbial α‐strain diversity and suppressed stool softening during H pylori eradication therapy.

Animals2区 · 农林科学

Repeated-Dose Pharmacodynamics of Pimobendan in Healthy Cats

2区 · 农林科学

ArticleOA

作者: Sugimoto, Keisuke ; Orito, Kensuke ; Fujii, Yoko ; Sugita, Kazutoshi

The aims of this study were to investigate the effects of repeated and multiple-dose pimobendan on cardiac systolic function and the correlations between changes in cardiac systolic function and plasma concentrations of pimobendan and O-desmethylpimobendan (ODMP). Five clinically healthy cats were subjected to four different medication protocols for 14 days, with a washout period of at least 1 month between each protocol. The protocols were pimobendan 0.5 mg/kg q12h (high dosage [HD] group); pimobendan 0.25 mg/kg q12h (standard dosage [SD] group); pimobendan 0.125 mg/kg q12h (low dosage group); and Biofermin R, one tablet q12h (placebo group). Echocardiography and measurement of plasma concentrations of pimobendan and ODMP were performed prior to medication administration (baseline) and 20, 40, 60, 120, 240, 360, and 480 min after administration, and the correlation between the changes in cardiac systolic function and plasma concentration of pimobendan, ODMP, or the sum of both were examined. The cardiac systolic function increased in the HD and SD groups, and there were significant correlations between the lateral peak systolic myocardial velocity (S′) changes and plasma pimobendan, plasma ODMP, and the sum of both. Repeated doses of pimobendan in healthy cats increased cardiac systolic function, and there were significant correlations between cardiac function and plasma concentrations of pimobendan and ODMP. The results of this study highlight the effectiveness of a higher dose of pimobendan.

100 项与耐性乳酸菌相关的药物交易

登录后查看更多信息